Abstract
Rebleeding has an important prognostic significance in patients with Upper Gastrointestinal Dieulafoy Lesions (UGIDLs). This study identifies that systemic factors—specifically kidney disease and infection—are major predictors of rebleeding and mortality in patients with UGIDLs, rather than the specific endoscopic technique employed.
Introduction
A Dieulafoy lesion (DL) is a rare but life-threatening gastrointestinal anomaly characterized by a large-caliber artery that fails to taper as it reaches the gut wall. This vessel eventually protrudes through the mucosal lining, leading to massive, spontaneous hemorrhage. Historically, DLs were associated with mortality rates as high as 80%. While advances in endoscopic therapy have reduced this to approximately 10%, these lesions remain notorious for "rebleeding"—the recurrence of hemorrhage after initial successful treatment.
Identifying which patients are at high risk for rebleeding is a critical clinical challenge. This research aimed to determine whether recurrence is driven by lesion characteristics, procedural techniques, or underlying patient comorbidities.
Methodology
This retrospective study analyzed 117 patients diagnosed with UGIDLs at Chonnam National University Hospital between 2004 and 2013. To ensure diagnostic accuracy, two experienced endoscopists reviewed each case against strict visual criteria, such as active arterial spurting from a minute mucosal defect.
The researchers employed multivariate logistic regression analysis to isolate independent predictors of rebleeding and mortality, controlling for variables such as age, gender, and specific comorbidities.
Key Findings
The study revealed several critical insights into the management and prognosis of UGIDLs:
- High Initial Success: Primary endoscopic treatment achieved hemostasis in 98.3% of patients.
- Systemic vs. Local Factors: There was no significant difference in rebleeding rates across different endoscopic modalities (e.g., hemoclips, band ligation, or injection therapy). This suggests that rebleeding is less a failure of the procedure and more a reflection of the patient's systemic health.
- The "Twin Terrors": Kidney disease and active infection emerged as the primary predictors of poor outcomes. Kidney disease likely impairs clot stability due to uremic platelet dysfunction, while infection creates a pro-inflammatory environment that hinders mucosal healing.
- Prognostic Significance of Rebleeding: Rebleeding serves as a powerful sentinel event. Patients who experienced a rebleed had a mortality rate of 30.0%, compared to 4.7% for those who did not (p=0.020).
Statistical Predictors of Outcomes
| Outcome | Predictor | Adjusted Odds Ratio (aOR) |
|---|---|---|
| Rebleeding | Kidney Disease | 11.35 |
| Infection | 12.32 | |
| Mortality | Kidney Disease | 15.43 |
| Low Platelet Count | 0.978 |
Clinical Implications and Future Directions
The findings underscore that rebleeding in UGIDL patients is a high-risk indicator often tied to systemic fragility. Clinical management should focus not only on the endoscopic site but also on aggressive stabilization of underlying conditions, particularly renal function and infection control.
Limitations
The study's retrospective nature and single-center design may limit the generalizability of the results. Furthermore, the heterogeneity of treatment methods used over the decade-long period complicates direct head-to-head comparisons of specific endoscopic tools.
Future Work
Prospective, multicenter studies are needed to validate these predictors and explore whether optimized medical management of comorbidities can directly lower rebleeding and mortality rates in this vulnerable patient population.
Summary updated